Baptist Health Hardin Launches World's First 4D Mammography Clinical Trial Using X-ray Diffraction Technology
核心洞察
Baptist Health Hardin has become the first hospital globally to begin in-human clinical trials of Calidar Inc. (搜索)'s revolutionary 4D Mammography (搜索) system that uses X-ray diffraction to detect molecular-level tissue fingerprints.
The investigational technology aims to identify breast cancer (搜索) earlier and more accurately by revealing tissue composition rather than just shape and density like traditional mammography.
The first-in-human study will enroll approximately 60 patients over several months to assess the system's potential to reduce unnecessary biopsies and improve diagnostic precision.
Baptist Health Hardin has achieved a historic milestone by becoming the first hospital worldwide to begin in-human clinical trials of a revolutionary breast imaging technology that could transform breast cancer (搜索) detection and diagnosis. The investigational 4D Mammography (搜索) system, developed by Calidar Inc. (搜索), uses X-ray diffraction to read molecular-level "fingerprints" in tissue, offering diagnostic information unavailable through currently approved imaging technology.
The trial launched with the successful imaging of the first patient using the 4D Mammography (搜索) system designed by Stefan Stryker, Josh Carpenter and Mitchell Greene of Calidar, Inc. This first clinical trial is expected to enroll approximately 60 patients over the next several months.
Revolutionary X-ray Diffraction Technology
The 4D Mammography (搜索) device uses X-ray diffraction to measure how X-rays scatter at the molecular level, producing a unique "signature" that reflects the internal composition of breast tissue (搜索). Unlike traditional X-ray images which rely on shape and density, this technology reveals what the tissue is made of — not just what it looks like — offering a new dimension of diagnostic data.
"This is more than a study milestone — this is the start of a new era of medical imaging," said Dr. Stryker, CEO of Calidar. "X-ray diffraction has unlocked some of the most iconic achievements in science — from discovering the structure of DNA to revealing the composition of another world on the Mars rover — and now we are bringing its power into the clinic to look inside the human body in a completely new way."
Addressing Critical Diagnostic Challenges
Breast cancer (搜索) remains difficult to diagnose without invasive procedures, leading to millions of unnecessary biopsies and delayed care each year. The 4D Mammography (搜索) technology is designed to improve the speed and precision of diagnoses by reducing the number of inconclusive imaging results. More conclusive results can mean fewer unnecessary biopsies, a faster path to treatment and a better chance for positive outcomes.
Dr. Stryker explained the technology's potential impact on false positives: "We envision our technology being used on the callback diagnostic, since the MRI has a lowering of the false positives, but not as much as X-ray diffraction, but we think our tool does a better job of knowing if the mass is cancerous or benign."
Clinical Trial Design and Objectives
The study is being conducted in collaboration with Baptist Health Hardin in Elizabethtown, Kentucky, led by Principal Investigator Craig Kamen, MD. The study will involve approximately 60 patients who meet specific criteria following 3D screening and diagnostic imaging that would typically lead to a biopsy. These patients have been referred by their doctor ahead of a biopsy.
"We are excited to collaborate on this next-generation research and contribute to the development of technology that could meaningfully enhance our capabilities for diagnosing breast cancer (搜索)," said Dr. Kamen.
Data from the trial will help determine the system's effectiveness and guide future studies including potential use in routine breast cancer (搜索) screening.
Institutional Commitment and Support
"We are honored to be participating in this first-in-human clinical trial focusing on advancing care for mammography patients," said Bert Jones, the hospital's director of Medical Imaging. "This groundbreaking research has the potential to change the course of treatment for countless people. Being part of this pivotal moment in medical innovation represents more than just scientific process — it's a step forward in improving the lives of women everywhere."
Hospital President Robert Ramey emphasized the institution's commitment to advanced care: "Baptist Health Hardin is committed to ensuring our patients have access to the most advanced technologies available. Being chosen as the first hospital in the world to conduct in-human trials of 4D Mammography (搜索) reflects the dedication of our physicians and staff to setting a new standard in patient care."
Baptist Health Foundation Hardin supported the project by funding a portion of the necessary renovations to house the new 4D Mammography (搜索) equipment and services.
Regulatory Status
The 4D Mammography (搜索) system is investigational and has not been cleared or approved by the U.S. Food and Drug Administration. It is not available for commercial sale and is limited to investigational use in the United States under FDA's abbreviated IDE requirements.